Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,068,686
  • Shares Outstanding, K 90,355
  • Annual Sales, $ 256,580 K
  • Annual Income, $ -76,970 K
  • 60-Month Beta 1.54
  • Price/Sales 15.90
  • Price/Cash Flow N/A
  • Price/Book 9.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.89
  • Number of Estimates 4
  • High Estimate -0.75
  • Low Estimate -1.07
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -56.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.20 +12.19%
on 07/31/20
48.00 -6.04%
on 08/07/20
+3.33 (+7.97%)
since 07/10/20
3-Month
32.12 +40.41%
on 06/08/20
48.00 -6.04%
on 08/07/20
+7.42 (+19.69%)
since 05/12/20
52-Week
22.65 +99.12%
on 03/19/20
48.95 -7.87%
on 12/10/19
-0.04 (-0.09%)
since 08/12/19

Most Recent Stories

More News
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids...

FGEN : 45.10 (+0.16%)
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 45.10 (+0.16%)
FibroGen Reports Second Quarter 2020 Financial Results

- Strong Second Quarter China Roxadustat Net Sales of $15.7 million -

FGEN : 45.10 (+0.16%)
SYBX : 2.21 (-7.92%)
FibroGen Announces New Appointments to its Board of Directors

- Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) -

FGEN : 45.10 (+0.16%)
SYBX : 2.21 (-7.92%)
FibroGen to Report Second Quarter 2020 Financial Results

FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m....

FGEN : 45.10 (+0.16%)
KKR Acquires Stake in First Gen through Voluntary Tender Offer

Global investment firm KKR today announced that, following the completion of the voluntary tender offer period by Valorous Asia Holdings (the "Offeror"), an entity owned by KKR investment funds, the Offeror...

FGEN : 45.10 (+0.16%)
KKR : 36.36 (+3.89%)
Theravance Doses First Patient in Phase II Coronavirus Study

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

AZN : 56.74 (+2.83%)
RHHBY : 43.3700 (+2.85%)
TBPH : 16.81 (-2.04%)
FGEN : 45.10 (+0.16%)
FibroGen Begins Phase II Study for Acute Coronavirus in US

FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.

AZN : 56.74 (+2.83%)
RHHBY : 43.3700 (+2.85%)
AMGN : 241.72 (+3.01%)
FGEN : 45.10 (+0.16%)
Fibrogen Inc Rises 3.81% on Heavy Volume: Watch For Potential Pullback

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $42.58 to a high of $43.84. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $42.30...

FGEN : 45.10 (+0.16%)
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19

FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients...

FGEN : 45.10 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade FGEN with:

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

2nd Resistance Point 46.42
1st Resistance Point 45.76
Last Price 45.10
1st Support Level 44.51
2nd Support Level 43.92

See More

52-Week High 48.95
Last Price 45.10
Fibonacci 61.8% 38.90
Fibonacci 50% 35.80
Fibonacci 38.2% 32.70
52-Week Low 22.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar